{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:02:11Z","timestamp":1793995331797,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13555-025-01342-0","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T16:24:23Z","timestamp":1738686263000},"page":"381-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Real-World Effectiveness of Risankizumab in Patients with Moderate-to-Severe Psoriasis: Interim Analysis from the VALUE Global Prospective Post-marketing Observational Study at 25\u00a0Months"],"prefix":"10.1007","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct03982394","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamitaro","family":"Ohtsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia-Tatjana","family":"Maul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Szegedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula C.","family":"Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles W.","family":"Lynde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug G.","family":"Ashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tshepiso","family":"Madihlaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Rubant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9557-3642","authenticated-orcid":false,"given":"Kim A.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"1342_CR1","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/j.1468-3083.2010.03705.x","volume":"24","author":"A Kimball","year":"2010","unstructured":"Kimball A, Gieler U, Linder D, Sampogna F, Warren R, Augustin M. Psoriasis: is the impairment to a patient\u2019s life cumulative? J Eur Acad Dermatol Venereol. 2010;24:989\u20131004.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1342_CR2","doi-asserted-by":"publisher","first-page":"adv00712","DOI":"10.2340\/actadv.v102.206","volume":"102","author":"MEV Muijen","year":"2022","unstructured":"Muijen MEV, Thomas SE, Groenewoud HMM, Otero ME, Ossenkoppele PM, Njoo MD, et al. Direct comparison of real-world effectiveness of biologics for psoriasis using absolute and relative psoriasis area and severity index scores in a prospective multicentre cohort. Acta Derm-Venereol. 2022;102:adv00712.","journal-title":"Acta Derm-Venereol."},{"key":"1342_CR3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/bjd.20387","volume":"185","author":"JT Maul","year":"2021","unstructured":"Maul JT, Augustin M, Sorbe C, Conrad C, Anzengruber F, Mrowietz U, et al. Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. Br J Dermatol. 2021;185:1160\u20138.","journal-title":"Br J Dermatol."},{"key":"1342_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s13555-021-00647-0","volume":"12","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Soliman AM, Betts KA, Wang Y, Gao Y, Stakias V, et al. Long-term benefit-risk profiles of treatments for moderate-to-severe plaque psoriasis: a network meta-analysis. Dermatol Ther. 2021;12:167\u201384.","journal-title":"Dermatol Ther"},{"key":"1342_CR5","first-page":"CD011535","volume":"2023","author":"E Sbidian","year":"2023","unstructured":"Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023;2023:CD011535.","journal-title":"Cochrane Database Syst Rev."},{"key":"1342_CR6","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/19420862.2015.1032491","volume":"7","author":"S Singh","year":"2015","unstructured":"Singh S, Kroe-Barrett RR, Canada KA, Zhu X, Sepulveda E, Wu H, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7:778\u201391.","journal-title":"MAbs."},{"key":"1342_CR7","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392:650\u201361.","journal-title":"Lancet."},{"key":"1342_CR8","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Thaci D, Crowley JJ, Ryan C, Krueger JG, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394:576\u201386.","journal-title":"Lancet."},{"key":"1342_CR9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, Beeck S, Kelly M, Wu T, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184:50\u20139.","journal-title":"Br J Dermatol."},{"key":"1342_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2022;186:466\u201375.","journal-title":"Br J Dermatol."},{"key":"1342_CR11","first-page":"571","volume":"19","author":"KA Papp","year":"2020","unstructured":"Papp KA, Langholff W. Safety surveillance for ustekinumab and other psoriasis treatments from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) Errata. J Drugs Dermatol. 2020;19:571\u20132.","journal-title":"J Drugs Dermatol."},{"key":"1342_CR12","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1111\/bjd.14068","volume":"173","author":"AB Kimball","year":"2015","unstructured":"Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. Br J Dermatol. 2015;173:1183\u201390.","journal-title":"Br J Dermatol."},{"key":"1342_CR13","doi-asserted-by":"crossref","unstructured":"Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, et al. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75\u201389 response: results from two phase 3 studies of secukinumab. J Dermatol Treat. 2017;28:492\u20139.","DOI":"10.1080\/09546634.2017.1294727"},{"key":"1342_CR14","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","volume":"14","author":"M Augustin","year":"2024","unstructured":"Augustin M, Gottlieb AB, Lebwohl M, Pinter A, Warren RB, Puig L, et al. Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis. Dermatol Ther. 2024;14:2841\u201357.","journal-title":"Dermatol Ther"},{"key":"1342_CR15","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s13555-024-01164-6","volume":"14","author":"A Pinter","year":"2024","unstructured":"Pinter A, Soliman AM, Pivneva I, Ghanbariamin R, Yang M, Truong B, et al. Real-world long-term effectiveness of risankizumab among patients with moderate-to-severe psoriasis: analysis from an international medical chart review (RAPID) study. Dermatol Ther. 2024;14:1259\u201371.","journal-title":"Dermatol Ther"},{"key":"1342_CR16","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","volume":"89","author":"KA Papp","year":"2023","unstructured":"Papp KA, Blauvelt A, Puig L, Ohtsuki M, Beissert S, Gooderham M, et al. Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol. 2023;89:1149\u201358.","journal-title":"J Am Acad Dermatol"},{"key":"1342_CR17","doi-asserted-by":"publisher","first-page":"2546161","DOI":"10.1155\/2019\/2546161","volume":"2019","author":"F Bai","year":"2019","unstructured":"Bai F, Li GG, Liu Q, Niu X, Li R, Ma H. Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res. 2019;2019:2546161.","journal-title":"J Immunol Res."},{"key":"1342_CR18","doi-asserted-by":"publisher","first-page":"1341708","DOI":"10.3389\/fimmu.2023.1341708","volume":"14","author":"L Gargiulo","year":"2024","unstructured":"Gargiulo L, Ibba L, Malagoli P, Balato A, Bardazzi F, Burlando M, et al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses\u2014IL PSO (Italian landscape psoriasis). Front Immunol. 2024;14:1341708.","journal-title":"Front Immunol"},{"key":"1342_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40265-024-02028-1","volume":"84","author":"SE Thomas","year":"2024","unstructured":"Thomas SE, Barenbrug L, Hannink G, Seyger MMB, de Jong EMGJ, van den Reek JMPA. Drug survival of IL-17 and IL-23 inhibitors for psoriasis: a systematic review and meta-analysis. Drugs. 2024;84:565\u201378.","journal-title":"Drugs"},{"key":"1342_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2147\/PTT.S356568","volume":"12","author":"CC de Ruiter","year":"2022","unstructured":"de Ruiter CC, Rustemeyer T. Biologics can significantly improve Dermatology Life Quality Index (DLQI) in psoriatic patients: a systematic review. Psoriasis Targets Ther. 2022;12:99\u2013112.","journal-title":"Psoriasis Targets Ther."},{"key":"1342_CR21","doi-asserted-by":"publisher","first-page":"1410540","DOI":"10.3389\/fimmu.2024.1410540","volume":"15","author":"L Raam","year":"2024","unstructured":"Raam L, Hartmane I, Valiukevi\u010dien\u0117 S, Karamova AE, Telegdy E, Botev I, et al. Disease severity, treatment patterns, and quality of life in patients with moderate-to-severe psoriasis routinely managed with systemic treatment: results of the CRYSTAL observational study in Central and Eastern European countries. Front Immunol. 2024;15:1410540.","journal-title":"Front Immunol"},{"key":"1342_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1177\/1203475418808764","volume":"23","author":"A Ighani","year":"2019","unstructured":"Ighani A, Yu AM, Sandhu VK, Barankin B, Manolson MF. Satisfaction and awareness of systemic psoriasis treatments: a national survey comparing biologic and nonbiologic users. J Cutan Med Surg. 2019;23:148\u201356.","journal-title":"J Cutan Med Surg"},{"key":"1342_CR23","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s13555-024-01238-5","volume":"14","author":"KB Gordon","year":"2024","unstructured":"Gordon KB, Blauvelt A, Bachelez H, Coates LC, den Bosch FEV, Kaplan B, et al. Long-term safety of risankizumab in patients with psoriatic disease: a comprehensive analysis from clinical trials. Dermatol Ther. 2024;14:2523\u201338.","journal-title":"Dermatol Ther"}],"updated-by":[{"DOI":"10.1007\/s13555-025-01420-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01342-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01342-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01342-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T02:55:07Z","timestamp":1746586507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01342-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1342"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01342-0","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-025-01420-3","URL":"https:\/\/doi.org\/10.1007\/s13555-025-01420-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Diamant Tha\u00e7i has been a consultant and an adviser and\/or received speaking fees and\/or grants and\/or served as an investigator in clinical trials for the following companies: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Galderma, Janssen-Cilag, LEO Pharma A\/S, L\u2019Oreal, Meiji, Newbridge, Novartis, Regeneron, Sanofi, Sun Pharma, Pfizer, Target RWE, UCB, and Vichy. He has received grants from AbbVie, LEO Pharma A\/S, and Novartis. Mamitaro Ohtsuki has received honoraria or fees for serving on advisory boards or speakers' bureaus, fees for consulting, and grants for investigator activities from AbbVie, Amgen, BI, BMS, Celgene, Eisai, Janssen, Kyowa Kirin, LEO, Lilly, Maruho, Mitsubishi Tanabe Pharma, Novartis, Pfizer, Sun Pharma, Taiho, Torii, and UCB. Julia-Tatjana Maul has served as an adviser and\/or received speaking fees and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, BMS, Celgene, Eli Lilly, LEO Pharma, Janssen-Cilag, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, and UCB. Andrea Szegedi has received a research grant from AbbVie and lecture and\/or consultant fees from Celgene, Eli Lilly, Janssen Pharmaceutical, LEO Pharma, AbbVie, Novartis, MSD, Pfizer, UCB, Galderma, and Sanofi. Paula C. Luna has received consulting fees, honoraria, or grant support or lecturing fees from Pierre Fabre Laboratory, Beiersdorf, Laboratoire La Roche Posay, Sanofi\u2013Genzyme, AbbVie, Novartis, Janssen, Pfizer, Elli Lilly, Boehringer Ingelheim, Takeda, Bristol Myers Squibb, Galderma, and GlaxoSmithKline. Dr. Charles W. Lynde has been a speaker and\/or consultant for AbbVie, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Eli Lilly, Fresnius Kabi, Galderma, GSK, InCyte, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L'Oreal, Medexus, MedX, Merck, Novartis,  P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, SunPharma,TEVA, Tribute, UCB, Valeant, Viatris, Volo Health. He has been a principal investigator for AbbVie, Acelyrin, Akros, Altius, Amgen, Aralez, Arcutis, Avillion, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Cipher, Concert, Dermavant, Devonian, Eli Lilly, Evelo, Galderma, GSK, InCyte, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche Posay, LEO Pharma, L'Oreal, Medexus, MedX, Merck, MoonLake, Nimbus, Novartis,  P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, SunPharma, Takeda, TEVA, Tribute, UCB, Valeant, Viatris, Volo Health. Ahmed M. Soliman, Hongwei Wang, Christian Kaufmann, Doug A. Ashley, Tshepiso Madihlaba, and Simone Rubant are employees of AbbVie and may own stock, stock options, or patents. Kim A. Papp has received honoraria and\/or grants from and is a consultant, investigator, or a scientific officer for AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health\/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Eli Lilly and Company, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte Corporation, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi-Aventis\/Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB Pharma, and Zai Lab. Orcid: 0000\u20130001-9557\u20133642.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This post-marketing observational study was conducted following the protocol and applicable local guidelines and regulations. Approvals were obtained from local ethics committees of the relevant countries, and the patients provided written informed consent at study initiation. The study was conducted in accordance with the International Conference on Harmonisation, Good Clinical Practice Guidelines, and the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}